Chugai's Polivy Receives MHLW's Approval for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Shots:
- The approval is based on results from P- Ib/II GO29365 study assessing Polivy (IV- 30 & 140mg) + BR vs BR alone in 80 DLBCL patients and P-II JO40762/P-DRIVE study that evaluated Polivy + BR therapy in 35 patients with R/R DLBCL not eligible for ASCT
- The P-II part of GO29365 study demonstrated CRR (40% vs 17.5%) at (PRA 6-8wks. after the last dose of Polivy). P-DRIVE study demonstrated 34% CRR at the PRA
- Additionally- the ongoing P-III GO39942/POLARIX study assesses the efficacy and safety of Polivy + R-CHP vs R-CHOP for untreated DLBCL
Ref: Chugai | Image: Wikipedia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com